Kodiak Sciences Inc (KOD) Stock Price, Quote & News

Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degenerati...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 281 0850

Website: kodiak.com

Address:

1250 Page Mill Road, Palo Alto, United States

John_Smithh Apr. 8 at 11:05 PM

$KOD I don’t think people realize the tremendous potential that Kodiak has . The ABC platform could shape the entire industry. Who would want an injection in the eye every month when you can get treated once every six months ? Once approved, Zenkuda could eat Vabysmo and Eylea’ s lunch … Good luck to all 🍀

1 · Reply

Uncle_Billy Apr. 8 at 5:07 PM

$KOD should be trading $60’s

1 · Reply

radonco Apr. 7 at 9:58 PM

$KOD MRTX 2.0…same hedgies…just wait.

0 · Reply

biomaster22 Apr. 7 at 8:57 PM

$KOD a little more perky would like it to perk up to $ 45 and consolidate there

0 · Reply

Stekli27 Apr. 7 at 4:57 PM

$KOD Large orders stepping in, shorts getting trapped. Strong absorption on every dip and clear floor forming around 41–42. This isn’t retail anymore, this is smart money building. Next leg up loading 🚀

1 · Reply

Cutlass Apr. 7 at 4:10 PM

$KOD Indeed, a bit Perky today 🎈

0 · Reply

Flipman10 Apr. 7 at 2:36 PM

$KOD I would say looking Perky

0 · Reply

AJT78 Apr. 7 at 2:20 PM

$KOD

0 · Reply

Stekli27 Apr. 7 at 2:15 PM

$KOD 👀

0 · Reply

BioTechHealthX Apr. 5 at 5:37 PM

$KOD Kodiak Sciences (NASDAQ: KOD) is gaining momentum after strong clinical results in diabetic eye disease. With improving patient outcomes and rising investor interest, could this biotech stock be gearing up for another breakout? https://biotechhealthx.com/biotech-news/should-you-now-try-to-invest-in-kodiak-sciences-kod/

0 · Reply

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

Mar 30, 2026, 10:00 AM EDT - 9 days ago

Kodiak Sciences: Road To $120

Mar 27, 2026, 10:40 AM EDT - 12 days ago

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Mar 26, 2026, 12:33 PM EDT - 13 days ago

Kodiak Sciences stock soars over 60%: what's behind the sharp rally

Mar 26, 2026, 8:12 AM EDT - 13 days ago

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Mar 26, 2026, 6:00 AM EDT - 14 days ago

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Feb 4, 2026, 7:00 AM EST - 2 months ago

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Jan 22, 2026, 10:26 AM EST - 2 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX LITE

Jan 7, 2026, 8:19 PM EST - 3 months ago

Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:26 PM EST - 3 months ago

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2025, 10:55 PM EST - 4 months ago

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Dec 15, 2025, 4:01 PM EST - 4 months ago

Kodiak Sciences Announces Proposed Public Offering of Common Stock

Nov 13, 2025, 4:05 PM EST - 5 months ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Nov 12, 2025, 5:48 PM EST - 5 months ago

Kodiak Sciences to Present at Upcoming Investor Conferences

Nov 5, 2025, 7:00 AM EST - 5 months ago

Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)

Oct 31, 2025, 12:01 PM EDT - 5 months ago

The Big 3: GOOGL, KOD, FTK

GOOG GOOGL FTK

Sep 15, 2025, 7:00 AM EDT - 7 months ago

New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)

Sep 2, 2025, 8:00 AM EDT - 7 months ago

Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)

Aug 27, 2025, 10:40 AM EDT - 8 months ago

Harbour BioMed Reports 2025 Interim Results

Aug 27, 2025, 6:54 AM EDT - 8 months ago

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

Aug 19, 2025, 2:18 PM EDT - 8 months ago

Kodiak Sciences to Present at American Chemical Society Fall 2025

Aug 13, 2025, 4:00 PM EDT - 8 months ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

Jul 10, 2025, 8:00 AM EDT - 9 months ago

Kodiak Sciences to Host Investor R&D Day on July 16, 2025

Jun 25, 2025, 4:45 PM EDT - 10 months ago

Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society

May 29, 2025, 9:32 PM EDT - 11 months ago

Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 14, 2025, 4:15 PM EDT - 11 months ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results

May 1, 2025, 11:43 PM EDT - 1 year ago

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Mar 27, 2025, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:39 PM EDT - 1 year ago

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Feb 4, 2025, 7:30 AM EST - 1 year ago

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Jan 7, 2025, 6:00 AM EST - 1 year ago

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 12:33 PM EST - 1 year ago

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Nov 14, 2024, 4:01 PM EST - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Nov 11, 2024, 6:15 AM EST - 1 year ago

Kodiak Sciences to Participate in Upcoming Investor Conferences

Oct 14, 2024, 5:35 PM EDT - 1 year ago

Kodiak Sciences to Present at Innovate Retina 2024

Sep 23, 2024, 6:00 AM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

May 29, 2024, 4:36 PM EDT - 2 years ago

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences

May 15, 2024, 4:01 PM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results

May 13, 2024, 7:32 PM EDT - 2 years ago

Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

May 2, 2024, 4:30 PM EDT - 2 years ago

Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Mar 28, 2024, 6:30 AM EDT - 2 years ago

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Mar 26, 2024, 6:15 AM EDT - 2 years ago

Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

Jan 30, 2024, 6:30 AM EST - 2 years ago

Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting

Jan 4, 2024, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 21, 2023, 4:15 PM EST - 2 years ago

Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:01 PM EST - 2 years ago

Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 6, 2023, 5:00 AM EST - 2 years ago

Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission

Nov 1, 2023, 11:21 PM EDT - 2 years ago

KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING

John_Smithh Apr. 8 at 11:05 PM

1 · Reply

Uncle_Billy Apr. 8 at 5:07 PM

$KOD should be trading $60’s

1 · Reply

radonco Apr. 7 at 9:58 PM

$KOD MRTX 2.0…same hedgies…just wait.

0 · Reply

biomaster22 Apr. 7 at 8:57 PM

$KOD a little more perky would like it to perk up to $ 45 and consolidate there

0 · Reply

Stekli27 Apr. 7 at 4:57 PM

1 · Reply

Cutlass Apr. 7 at 4:10 PM

$KOD Indeed, a bit Perky today 🎈

0 · Reply

Flipman10 Apr. 7 at 2:36 PM

$KOD I would say looking Perky

0 · Reply

AJT78 Apr. 7 at 2:20 PM

$KOD

0 · Reply

Stekli27 Apr. 7 at 2:15 PM

$KOD 👀

0 · Reply

BioTechHealthX Apr. 5 at 5:37 PM

0 · Reply

biomaster22 Apr. 2 at 9:39 PM

$KOD not very perky today Cutlass

0 · Reply

ShowMeThaMonay Apr. 2 at 4:18 PM

$KODK people getting this mixed up with Kodiak $KOD or what 😂

1 · Reply

Marseea1 Apr. 2 at 4:03 PM

$KOD will fade into the weekend. Profit taking

0 · Reply

Stekli27 Apr. 2 at 2:43 PM

$KOD

0 · Reply

ClutchBallz Apr. 2 at 1:39 PM

$KOD This needs to hold 40. Else I could see 35 today

1 · Reply

BioTechHealthX Apr. 2 at 8:59 AM

$CVM $KOD $SGMO $VSA $WINT These top 5 biotech stocks combine strong catalysts, clinical progress, and growth potential. Find out which companies could deliver massive returns. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-that-could-deliver-1000-returns/

1 · Reply

BioTechHealthX Apr. 2 at 8:28 AM

$CVM $KOD $TBPH $VSA $WINT From high-risk moonshots to late-stage clinical winners, these top 5 biotech stocks are capturing massive investor attention. Discover which companies are nearing breakthroughs, regulatory catalysts, and explosive upside potential before the crowd catches on. https://biotechhealthx.com/biotech-news/top-5-biotech-stocks-to-watch-now/

0 · Reply

GlobalMarketBulletin Apr. 2 at 6:06 AM

$BF.B $KOD $NAVN $NEXT $VSA These 5 penny stocks are quietly building momentum with breakthrough catalysts, AI expansion, biotech innovation, and massive upside potential. Discover why investors are hunting for the next 10x to 100x opportunities before the crowd catches on. https://globalmarketbulletin.com/top-5-hottest-stocks-dominating-the-market-today/

0 · Reply

stock_jinx Apr. 1 at 8:52 PM

$KOD Yet another shorting gift tomorrow am!

0 · Reply

Stekli27 Apr. 1 at 7:32 PM

$KOD every time someone says “easy short” this thing just goes higher… keep it coming 🤣🔥

1 · Reply

Marseea1 Apr. 1 at 7:16 PM

$KOD short

0 · Reply

womeninfinance Apr. 1 at 7:08 PM

$KOD watching a bullish pennant on the 15-min — if it doesn’t break today, could see a move tomorrow toward 49.67$ resistance 🙈

0 · Reply

Market Cap	2.58B
Revenue (ttm)	0.00
Net Income (ttm)	-229.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	891,900
Avg Vol	1,167,992
Day's Range	N/A - N/A
Shares Out	61.85M
Stochastic %K	69%
Beta	2.39
Analysts	Sell
Price Target	$50.71